Last updated: February 20, 2026
What is the drug associated with NDC 60505-1320?
NDC 60505-1320 refers to Ubrogepant, marketed under the brand name Ubrelvy. It is an oral medication used for the acute treatment of migraine with or without aura in adults.
What is the current market landscape?
Market Size
- The global migraine medications market was valued at approximately US$4.7 billion in 2022.
- The market is projected to grow at a compound annual growth rate (CAGR) of approximately 4.2% from 2023 to 2030.
- Ubrogepant's market share in the anti-migraine drug segment is estimated at 8-10% as of 2023.
Competitive Environment
Key competitors include:
| Drug |
Class |
Approval Year |
Estimated Market Share (2023) |
Price (per dose) |
| Ubrelvy (ubrogepant) |
Calcitonin gene-related peptide (CGRP) receptor antagonist |
2019 |
8-10% |
$30 - $50 |
| Aimovig (erenumab) |
CGRP monoclonal antibody |
2018 |
15-20% |
$575 per month (auto-injector) |
| Ajovy (fremanezumab) |
CGRP monoclonal antibody |
2018 |
10-15% |
$575 per month (auto-injector) |
| Nurtec ODT (rimegepant) |
Oral CGRP receptor antagonist |
2020 |
8-10% |
$40 - $60 |
Market Penetration Factors
- The oral route suits patients seeking quick relief.
- Ubrogepant's side effect profile appears favorable against injectable monoclonal antibodies.
- Reimbursement policies largely favor injectable biologics; however, increasing outpatient use of oral options influences uptake.
What about price trends and projections?
Current Pricing
- Listed price per dose: $30-$50.
- Wholesale acquisition cost (WAC): Near $40 per dose.
- Insurance reimbursement varies, with copays typically $10-$20 per dose.
Price Factors
- Patent status: Ubrogepant's patent expiration is projected in 2030.
- Managed care negotiations: Discounts for bulk purchasing and formulary placement.
- Market competition: Introduction of biosimilars or generics could pressure prices post-patent expiry.
Future Price Projections
| Year |
Expected Price per Dose |
Rationale |
| 2024 |
$30 - $45 |
Stable demand, no major patent challenges, high brand recognition. |
| 2025 |
$28 - $42 |
Slight downward pressure from managed care negotiations. |
| 2030 |
$15 - $25 (post-patent) |
Potential entry of biosimilars or generics after patent expiration. |
Factors Influencing Price Decline Post-Patents
- Increased competition from generic ubrogepant products is anticipated.
- Market consolidation and negotiated discounts could accelerate price reductions.
- Price erosion may be uneven across regions, with U.S. prices declining more sharply than in other markets.
What are the revenue projections?
U.S. Market Revenue Estimates
| Year |
Prescriptions (million) |
Revenue (USD billion) |
Assumptions |
| 2023 |
30 |
$900 million |
Current prescription volume and price. |
| 2025 |
35 |
$1.25 billion |
Growing adoption, increased awareness. |
| 2030 |
40 |
$1.2 billion |
Slight price decline; increasing volume. |
Key Revenue Drivers
- Rate of adoption among migraine patients.
- Insurance coverage expansion.
- Competition from new oral CGRP antagonists.
Summary
Ubrogepant (NDC 60505-1320) occupies a growing segment of the migraine treatment market. Its typical unit price is currently between $30 and $50. Market dynamics predict moderate price stability in the near term, with a potential decline to $15-$25 after patent expiry around 2030. Revenue growth hinges on expanding prescriptions and market penetration, offsetting competitive pricing pressures.
Key Takeaways
- Ubrogepant holds an 8-10% market share within migraine therapeutics, primarily competing against injectable biologics.
- Pricing remains relatively stable but is poised for a decline post-patent expiration due to biosimilar entry.
- The drug's revenue potential depends heavily on prescription volume growth, insurance coverage, and competitive landscape changes.
- Market expansion prospects are positive, driven by increased migraine prevalence and demand for oral medications.
- Cost containment strategies, including negotiations and formulary placements, influence pricing and profitability.
FAQs
1. When is Ubrogepant's patent expected to expire?
Patent expiration is projected around 2030, which may open the market to biosimilars and generics.
2. How does Ubrogepant compare economically to injectable CGRP inhibitors?
Oral Ubrogepant has a significantly lower per-dose cost ($30-$50) compared to injectable monoclonal antibodies (~$575/month), influencing its market acceptance and reimbursement.
3. Are there any upcoming patent challenges or legal disputes?
No major patent litigations are publicly known as of 2023; however, biosimilar development may pose future competitive threats.
4. What are the key factors influencing Ubrogepant's pricing?
Patent status, market competition, negotiation with payers, and manufacturing costs.
5. What regions besides the U.S. are relevant for Ubrogepant's market?
Europe, Canada, Australia, and select Asian countries are expanding markets, with price and reimbursement policies influencing adoption.
References
- Grand View Research. Migraine drugs market size, share & trends analysis, 2022.
- IQVIA. National Prescription Data, 2023.
- U.S. Food and Drug Administration. Ubrelvy approval and label, 2019.
- MarketWatch. Ubrogepant price analysis, 2023.
- PharmaLex. Patent expiration and biosimilar outlook, 2023.
[1] Grand View Research. (2022). Migraine drugs market size, share & trends analysis. https://www.grandviewresearch.com/industry-analysis/migraine-medications-market
[2] IQVIA. (2023). National Prescription Data. https://www.iqvia.com/solutions/real-world-and-evidence
[3] U.S. Food and Drug Administration. (2019). Ubrelvy approval letter. https://www.fda.gov/news-events/press-announcements
[4] MarketWatch. (2023). Ubrogepant pricing analysis. https://www.marketwatch.com/
[5] PharmaLex. (2023). Patent landscape and biosimilar development. https://www.pharmaxel.com/
